News

June 24, 2019

Researchers Work to Create Screening Tool for Early or Pre-cancerous OC

News

Researchers from Clemson University and doctors from South Carolina’s Prisma Health-Upstate are collaborating to develop a screening tool that can identify ovarian cancer in its earlier stages, or even ... Read more

June 19, 2019

Lynparza Approved in Europe as Initial Maintenance Therapy for Some OC

News

Women in the European Union with BRCA-mutated advanced ovarian cancer can now receive Lynparza (olaparib) as a first-line maintenance treatment, AstraZeneca and Merck (known as MSD outside the U.S. and ... Read more

June 17, 2019

Sentinel Node Biopsy Feasible to Determine Spread of Early-stage OC

News

A sentinel node biopsy, used to determine whether cancer has spread to lymph nodes, is a feasible way to obtain information and avoid lymph node dissection in patients with ... Read more

June 14, 2019June 14, 2019

First Patient Dosed in Phase 2 Trial Evaluating Ampligen-Keytruda-Chemo Combo for Ovarian Cancer

News

The first patient has been dosed with Hemispherx Biopharma‘s experimental treatment Ampligen (rintatolimod), in combination with Keytruda (pembrolizumab) and cisplatin, for recurrent ovarian cancer. The investigator-sponsored Phase 2 trial ... Read more

June 13, 2019June 21, 2019

Groups to Jointly Invest $8 Million in Ovarian Cancer Research Projects

News

To help find innovative ways to detect, treat, and prevent ovarian cancer, the Ovarian Cancer Research Alliance and the American Cancer Society plan to jointly invest $8 million in ... Read more

June 12, 2019

Rubraca Maintenance Delays Disease Progression in Subsequent Treatments for Recurrent OC, Phase 3 Trial Shows

News

Maintenance treatment with Rubraca (rucaparib) delays the need for additional treatments among women with platinum-sensitive recurrent ovarian cancer — and then extends the time to disease worsening after those ... Read more

June 7, 2019

Immune Checkpoint Molecules Have Prognostic Value in Ovarian Cancer, Study Reports

News

The immune checkpoint molecules PD-L1 and TIM-3 have prognostic value in people with ovarian cancer who have not yet received chemotherapy. But while low levels of TIM-3 were linked ... Read more

June 5, 2019June 5, 2019

Lynparza Better Than Chemo for BRCA-mutated Advanced Ovarian Cancer, Phase 3 Trial Shows

News

Lynparza (olaparib), given to advanced ovarian cancer patients with BRCA mutations who were previously treated with at least two lines of platinum chemotherapy, had significantly better response rates and progression-free ... Read more

June 3, 2019

OncBioMune’s Experimental Chemo Shows Potential to Inhibit Growth of Drug-resistant OC Cells

News

PGT, an experimental chemotherapy developed by OncBioMune, inhibited the growth of ovarian cancer cells resistant to multiple chemotherapeutic agents. These preliminary results suggest that the therapy could potentially be ... Read more

May 31, 2019June 3, 2019

DPX-Survivac Elicits Anti-Cancer Immune Activity in Recurrent OC, Data Show

News

DPX-Survivac combined with intermittent low-dose cyclophosphamide can generate significant anti-tumor immune responses that correlate with tumor regression in women with recurrent advanced ovarian cancer, latest results from the DECIDE1 ... Read more

Pin It on Pinterest